nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.11.2011 | Original Paper

Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors

verfasst von: Thierry Marysael, Yicheng Ni, Evelyne Lerut, Peter de Witte

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated the influence of two types of vascular damaging agents (VDAs) (DMXAA vs. ZD6126) and sequence of administration (VDA 24 h before HYP vs. HYP 1 h before VDA) to evaluate the effect on hypericin (HYP) accumulation and distribution in necrotic tumors.

Methods

Frozen sections of dorsally inoculated RIF-1 tumors were analyzed by fluorescence microscopy and H&E stained for histological evaluation. The localization of HYP was assessed both qualitatively and semi-quantitatively in necrotic tumor, viable tumor, or nontarget host tissue.

Results

Whereas the type of VDA did not influence HYP accumulation and distribution, a clear advantage could be seen when administering VDA 24 h before HYP compared to HYP 1 h before VDA, pointing toward the absence of a “trapping” mechanism. In DMXAA-treated and not in ZD6126-treated tumors, spotty fluorescence was observed which is likely to be a consequence of neutrophil phagocytosis. Dexamethasone treatment neither did influence this phenomenon nor did change HYP uptake in necrotic tumor.

Conclusions

We conclude that HYP accumulation is optimal when it is administered after VDA injection. We also found that HYP accumulation in necrosis is not changed when using VDAs with different working mechanisms. This insight provides a rationale for tumor necrosis therapy (TNT) using iodine-131-labeled hypericin ([¹³¹I]-HYP) in combination with VDAs.

Chen FM, Taylor CR, Epstein AL (1989) Tumor necrosis treatment of ME-180 human cervical carcinoma model with ¹³¹I-labeled TNT-1 monoclonal antibody. Cancer Res 49(16):4578–4585PubMed

Chen B, Xu Y, Roskams T, Delaey E, Agostinis P, Vandenheede JR, de Witte P (2001) Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int J Cancer 93(2):275–282. doi:10.1002/ijc.1324 PubMedCrossRef

Ching LM, Zwain S, Baguley BC (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90(4):906–910. doi:10.1038/sj.bjc.6601606 PubMedCrossRef

Cooper EH, Bedford AJ, Kenny TE (1975) Cell death in normal and malignant tissues. Adv Cancer Res 21:59–120PubMedCrossRef

Epstein AL, Chen FM, Taylor CR (1988) A novel method for the detection of necrotic lesions in human cancers. Cancer Res 48(20):5842–5848PubMed

Falk H, Meyer J, Oberreiter M (1993) A convenient semisynthetic route to hypericin. Monatshefte Fur Chemie 124(3):339–341CrossRef

Finotto S, Mekori YA, Metcalfe DD (1997) Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 99(7):1721–1728. doi:10.1172/JCI119336 PubMedCrossRef

Fonge H, Vunckx K, Wang H, Feng Y, Mortelmans L, Nuyts J, Bormans G, Verbruggen A, Ni Y (2008) Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I] iodohypericin microSPECT. Eur Heart J 29(2):260–269. doi:10.1093/eurheartj/ehm588 PubMedCrossRef

Hdeib A, Sloan AE (2011) Convection-enhanced delivery of [¹³¹I]-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opin Biol Ther 11(6):799–806. doi:10.1517/14712598.2011.579097 PubMedCrossRef

Horsman MR, Murata R (2003) Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57(4):1047–1055. doi:10.1016/S0360-3016(03)00769-7 PubMedCrossRef

Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66(24):11520–11539. doi:10.1158/0008-5472.CAN-06-2848 PubMedCrossRef

Jain M, Venkatraman G, Batra SK (2007) Optimization of radio immunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res 13(5):1374–1382. doi:1078-0432.CCR-06-2436 PubMedCrossRef

Kanthou C, Tozer GM (2009) Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 90(3):284–294. doi:10.1111/j.1365-2613.2009.00651.x PubMedCrossRef

Koljenovic S, Choo-Smith LP, Bakker Schut TC, Kros JM, van den Berge HJ, Puppels GJ (2002) Discriminating vital tumor from necrotic tissue in human glioblastoma tissue samples by Raman spectroscopy. Lab Invest 82(10):1265–1277PubMed

Li J, Sun Z, Zhang J, Shao H, Miranda Cona M, Wang H, Marysael T, Chen F, Prinsen K, Zhou L, Huang D, Nuyts J, Yu J, Meng B, Bormans G, Fang Z, de Witte P, Li Y, Verbruggen A, Wang X, Mortelmans L, Xu K, Marchal G, Ni Y (2011) A dual-targeting anticancer approach: soil and seed principle. Radiology 260:799–807. doi:radiol.11102120 PubMedCrossRef

McKeage MJ, Baguley BC (2010) Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116(8):1859–1871. doi:10.1002/cncr.24975 PubMedCrossRef

Miller TA, Schaefer FW III (2007) Changes in mouse circulating leukocyte numbers in C57BL/6 mice immunosuppressed with dexamethasone for Cryptosporidium parvum oocyst production. Vet Parasitol 149(3–4):147–157. doi:10.1016/j.vetpar.2007.08.017 PubMedCrossRef

Miyachi Y (2000) Pharmacologic modulation of neutrophil functions. Clin Dermatol 18(3):369–373PubMedCrossRef

Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G (2005) Necrosis avid contrast agents: functional similarity versus structural diversity. Invest Radiol 40(8):526–535PubMedCrossRef

Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L, Chen F, Marchal G, Verbruggen AM, Bormans GM (2006) First preclinical evaluation of mono-[123I] iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 33(5):595–601. doi:10.1007/s00259-005-0013-2 PubMedCrossRef

Song S, Xiong C, Zhou M, Lu W, Huang Q, Ku G, Zhao J, Flores LG Jr, Ni Y, Li C (2011) Small-animal PET of tumor damage induced by photothermal ablation with 64Cu-bis-DOTA-hypericin. J Nucl Med 52(5):792–799. doi:jnumed.110.086116 PubMedCrossRef

Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5(6):423–435. doi:10.1038/nrc1628 PubMedCrossRef

Van de Putte M, Roskams T, Vandenheede JR, Agostinis P, de Witte PA (2005) Elucidation of the tumoritropic principle of hypericin. Br J Cancer 92(8):1406–1413. doi:10.1038/sj.bjc.6602512 PubMedCrossRef

Van de Putte M, Ni Y, De Witte PA (2008a) Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncol Rep 19(4):921–926PubMed

Van de Putte M, Wang H, Chen F, de Witte PA, Ni Y (2008b) Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. Acad Radiol 15(1):107–113. doi:10.1016/j.acra.2007.08.008 PubMedCrossRef

Van de Putte M, Wang H, Chen F, De Witte PA, Ni Y (2008c) Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep 19(4):927–932PubMed

Wang H, Cao C, Li B, Chen S, Yin J, Shi J, Ye D, Tao Q, Hu P, Epstein A, Ju D (2008) Immunogenicity of iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients. Cancer Immunol Immunother 57(5):677–684. doi:10.1007/s00262-007-0406-0 PubMedCrossRef

Wang LC, Thomsen L, Sutherland R, Reddy CB, Tijono SM, Chen CJ, Angel CE, Dunbar PR, Ching LM (2009) Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). Neoplasia 11(8):793–803PubMed

Wang H, Li J, Chen F, De Keyzer F, Yu J, Feng Y, Nuyts J, Marchal G, Ni Y (2010) Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol 20(8):2013–2026. doi:10.1007/s00330-010-1743-5 PubMedCrossRef

Titel: Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors
verfasst von: Thierry Marysael
Yicheng Ni
Evelyne Lerut
Peter de Witte
Publikationsdatum: 01.11.2011
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-1032-y

Springer Medizin

Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2011

Microelectromechanical system-based diagnostic technology for cervical cancer

Gastrokine 1 functions as a tumor suppressor by inhibition of epithelial–mesenchymal transition in gastric cancers

Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?

BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231

PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer

BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie